CorMedix (NASDAQ:CRMD) Stock: Insider Myron Kaplan Acquires 25,000 Shares

CorMedix Inc (NASDAQ:CRMD – Get Free Report) Director Myron Kaplan bought 25,000 shares of the stock in a transaction on Monday, November 16th. The shares were bought at an average price of $4.88 per share, with a total value of $122,000.00. Following the acquisition, the director owned 256,487 shares of the company’s stock, valued at $1,251,656.56. This trade represents a 10.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

CorMedix Stock Up 12.9%

Shares of NASDAQ CRMD opened at $5.08 on Friday. The company has a current ratio of 2.43, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $404.06 million, a PE ratio of 3.49, a price-to-earnings-growth ratio of 1.03 and a beta of 1.48. The stock’s fifty day simple moving average is $6.91 and its two-hundred day simple moving average is $7.50. CorMedix Inc has a 12-month low of $4.47 and a 12-month high of $13.02.

CorMedix (NASDAQ:CRMD – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The company had revenue of $54.52 million during the quarter, compared to analysts’ expectations of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 26.70%. As a group, analysts expect that CorMedix Inc will post 0.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. lifted its position in CorMedix by 150.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company’s stock worth $3,443,000 after acquiring an additional 263,618 shares during the period. BlackRock Inc. purchased a new stake in CorMedix during the 2nd quarter valued at about $49,644,000. Bank of America Corp DE acquired a new position in shares of CorMedix in the second quarter valued at about $1,183,000. Bank of New York Mellon Corp acquired a new position in shares of CorMedix in the second quarter valued at about $3,108,000. Finally, Pacer Advisors Inc. increased its holdings in shares of CorMedix by 128.7% in the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock valued at $3,942,000 after purchasing an additional 326,724 shares during the period. Hedge funds and other institutional investors own 34.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CRMD shares. Needham & Company LLC boosted their target price on shares of CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Wall Street Zen cut shares of CorMedix from a “hold” rating to a “sell” rating in a report on Saturday, November 14th. Citigroup restated a “market outperform” rating on shares of CorMedix in a report on Tuesday, November 10th. Royal Bank Of Canada lifted their price objective on shares of CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. Finally, Weiss Ratings lowered shares of CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, CorMedix presently has an average rating of “Moderate Buy” and an average price target of $15.22.

Get Our Latest Research Report on CRMD

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Featured Articles

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.